Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Utkarsh Goel, Danai Dima, James A Davis, Aliya Rashid, William Wesson, Shaun DeJarnette, Fauzia Ullah, Evguenia Ouchveridze, Mariam Markouli, Claire Yun Kyoung Ryu Tiger, Louis Williams, Sandra Mazzoni, Beth M. Faiman, Craig Sauter, Faiz Anwer, Shahzad Raza, Leyla O. Shune, Jack Khouri

Blood (2024) 144 (Supplement 1): 4708.

https://doi.org/10.1182/blood-2024-203984

Published: 2024

Journal Articles

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Blood (2024) 144 (Supplement 1): 5170.5.

https://doi.org/10.1182/blood-2024-211053

Published: 2024

Journal Articles

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Rachel Dileo, Prerna Mewawalla, Gina Patrus, Christopher Strouse, Ethan Chen, Hira Shaikh, James A Davis, Kimberly M Green, Omar Alkharabsheh, Aliya Rashid, Bidushi Pokhrel, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2024-206059

Published: 2024

Journal Articles

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Ishita Kamboj, Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, James A Davis, Aliya Rashid, Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Abdullah Mohammad Khan, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 2411.2.

https://doi.org/10.1182/blood-2024-199187

Published: 2024

Journal Articles

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Aliya Rashid, William Wesson, Forat Lutfi, Muhammad Umair Mushtaq, Joseph P McGuirk, Al-Ola Abdallah, Wei Cui, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6801.

https://doi.org/10.1182/blood-2023-182126

Published: 2023

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Danai Dima, Aliya Rashid, James A Davis, Hussein Awada, Al-Ola Abdallah, Hong Li, Shaun DeJarnette, Leyla Shune, Jack Khouri, Hamza Hashmi, Joseph P McGuirk, Faiz Anwer, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2023-180368

Published: 2023

Journal Articles

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Danai Dima, James A Davis, Aliya Rashid, Mikhaila Rice, Shaun DeJarnette, Leyla Shune, Jack Khouri, Shahzad Raza, Joseph P McGuirk, Faiz Anwer, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 4882.

https://doi.org/10.1182/blood-2023-181331

Published: 2023

Journal Articles

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma

William Wesson, Aliya Rashid, Md Saiful Islam Saif, Emerson Logan, Carine Tabak, Mary McGann, James A Davis, Liz Hazlett, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Marc S. Hoffmann, Hamza Hashmi, Joseph P McGuirk, Mehdi Hamadani, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6914.

https://doi.org/10.1182/blood-2023-182872

Published: 2023

Journal Articles

Use of Eltrombopag for Post-CAR T Cytopenias: A Multi-Institutional Experience

William Wesson, Nausheen Ahmed, James A Davis, Mary McGann, Aliya Rashid, Carine Tabak, Emerson Logan, Jose Marchena-Burgos, Maggie Nelson, Leyla Shune, Marc S. Hoffmann, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2023-181283

Published: 2023

Journal Articles

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Aroog Khaliq, William Wesson, Emerson Logan, Carine Tabak, Aliya Rashid, Razan Mansour, Muhammad Umair Mushtaq, Joseph P McGuirk, Hamza Hashmi, Mehdi Hamadani, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2023-179409

Published: 2023

Journal Articles

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Mohammad Ahsen Soomro, Shebli Atrash, Aliya Rashid, William Wesson, Hamza Hashmi, Aimaz Afrough, Barry S. Skikne, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6900.

https://doi.org/10.1182/blood-2023-180306

Published: 2023

Journal Articles

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Forat Lutfi, Briha Ansari, Afraah Hawa, Al-Ola Abdallah, Zubair Shah, Andre Khazak, Hussam Hawamdeh, Marc S. Hoffmann, Muhammad Umair Mushtaq, William Wesson, Aliya Rashid, Maggie Nelson, Leyla Shune, Sunil Abhyankar, Joseph P McGuirk, Charles Porter, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6916.

https://doi.org/10.1182/blood-2023-188031

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience

Razan Mansour, James A Davis, Megan Minchak, Rawan Atallah, Md Saiful Islam Saif, Emerson Logan, Carine Tabak, Aliya Rashid, Danai Dima, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2023-179661

Published: 2023

NARROW

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma

Use of Eltrombopag for Post-CAR T Cytopenias: A Multi-Institutional Experience

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only